The trial plans to enroll nasopharyngeal carcinoma patients with first-diagnosed metastasis or recurrence/metastasis after local treatment and never receive systemic treatment for recurrent/metastatic lesion. Patients will be treated with anlotinib, penpulimab and capecitabine every three weeks until PD or intolerance to toxicity.
First-diagnosed metastasis or recurrence/metastasis NPC Patients will be treated with anlotinib, penpulimab and capecitabine.